Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
Published
Published: Guidance, quality standards and advice
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter
Skip to results
Keyword or reference number
Keyword or reference number
Apply filter
Last updated date
Last updated date
From date
To date
Apply date filters
Area of interest
Area of interest
Antimicrobial prescribing (39)
COVID-19 (12)
Type
Type
Guidance (1898)
NICE advice (321)
Quality standard (198)
Guidance programme
Guidance programme
Antimicrobial prescribing guidelines (20)
Cancer service guidelines (8)
Clinical guidelines (225)
COVID-19 rapid guidelines (3)
Diagnostics guidance (50)
Health technology evaluations (18)
Highly specialised technologies guidance (28)
Interventional procedures guidance (603)
Medical technologies guidance (67)
Medicines practice guidelines (5)
NICE guidelines (341)
Public health guidelines (61)
Safe staffing guidelines (2)
Social care guidelines (71)
Technology appraisal guidance (791)
Advice programme
Advice programme
Evidence summaries (68)
Medtech innovation briefings (253)
Apply filters
Showing 51 to 100 of 2417
Sort by
Date
Title
Apply sorting
Published guidance, NICE advice and quality standards
Title
Reference number
Published
Last updated
Zanubrutinib with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma after 2 or more treatments (terminated appraisal)
TA978
29 May 2024
29 May 2024
Sirolimus for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over (terminated appraisal)
TA972
22 May 2024
22 May 2024
Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome
HST31
22 May 2024
22 May 2024
Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis
TA127
22 August 2007
21 May 2024
Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis
TA312
28 May 2014
21 May 2024
Cladribine for treating relapsing–remitting multiple sclerosis
TA616
19 December 2019
21 May 2024
Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion
TA283
22 May 2013
20 May 2024
Ranibizumab and pegaptanib for the treatment of age-related macular degeneration
TA155
27 August 2008
20 May 2024
Ranibizumab for treating choroidal neovascularisation associated with pathological myopia
TA298
27 November 2013
20 May 2024
Selective internal radiation therapy for neuroendocrine tumours that have metastasised to the liver
IPG786
16 May 2024
16 May 2024
Endoscopic duodenal mucosal resurfacing for insulin resistance in type 2 diabetes
IPG787
16 May 2024
16 May 2024
Image-guided percutaneous laser ablation for primary and secondary liver tumours
IPG788
16 May 2024
16 May 2024
Atogepant for preventing migraine
TA973
15 May 2024
15 May 2024
Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma
TA974
15 May 2024
15 May 2024
Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under
TA975
15 May 2024
15 May 2024
Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer
DG58
9 May 2024
9 May 2024
Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments
TA970
8 May 2024
8 May 2024
Remdesivir and tixagevimab plus cilgavimab for treating COVID-19
TA971
8 May 2024
8 May 2024
COVID-19 rapid guideline: managing COVID-19
NG191
23 March 2021
8 May 2024
Artificial intelligence (AI)-derived software to help clinical decision making in stroke
DG57
23 January 2024
2 May 2024
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over
TA967
1 May 2024
1 May 2024
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma
TA540
3 September 2018
1 May 2024
Digital technologies to deliver pulmonary rehabilitation programmes for adults with COPD: early value assessment
HTE18
30 April 2024
30 April 2024
Gefapixant for treating refractory or unexplained chronic cough (terminated appraisal)
TA969
30 April 2024
30 April 2024
Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)
TA968
25 April 2024
25 April 2024
Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer (terminated appraisal)
TA966
24 April 2024
24 April 2024
Lymphovenous anastomosis during axillary or inguinal node dissection for preventing secondary lymphoedema
IPG785
16 April 2024
16 April 2024
Endometriosis: diagnosis and management
NG73
6 September 2017
16 April 2024
Cabozantinib with nivolumab for untreated advanced renal cell carcinoma
TA964
10 April 2024
10 April 2024
Twin and triplet pregnancy
NG137
4 September 2019
9 April 2024
Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency
TA963
3 April 2024
3 April 2024
Kurin Lock for blood culture collection
MTG77
3 April 2024
3 April 2024
GaitSmart rehabilitation exercise programme for gait and mobility issues
MTG78
3 April 2024
3 April 2024
Epidermal radiotherapy using rhenium-188 paste for non-melanoma skin cancer
IPG784
2 April 2024
2 April 2024
Sebelipase alfa for treating lysosomal acid lipase deficiency that is not Wolman disease (terminated appraisal)
TA961
28 March 2024
28 March 2024
Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy
TA962
28 March 2024
28 March 2024
Human alpha1-proteinase inhibitor for treating emphysema (terminated appraisal)
TA965
28 March 2024
28 March 2024
Ritlecitinib for treating severe alopecia areata in people 12 years and over
TA958
27 March 2024
27 March 2024
Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis
TA959
27 March 2024
27 March 2024
Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders (terminated appraisal)
TA960
27 March 2024
27 March 2024
Desflurane for maintenance of anaesthesia
ES41
26 March 2024
26 March 2024
Digital health technologies to help manage symptoms of psychosis and prevent relapse in adults and young people: early value assessment
HTE17
25 March 2024
25 March 2024
Ovarian cancer: identifying and managing familial and genetic risk
NG241
21 March 2024
21 March 2024
Momelotinib for treating myelofibrosis-related splenomegaly or symptoms
TA957
20 March 2024
20 March 2024
Suspected sepsis: recognition, diagnosis and early management
NG51
13 July 2016
19 March 2024
Neonatal infection: antibiotics for prevention and treatment
NG195
20 April 2021
19 March 2024
Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management
NG240
19 March 2024
19 March 2024
ProKnow cloud-based system for radiotherapy data storage, communication and management: early value assessment
HTE5
28 March 2023
14 March 2024
Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19
TA878
29 March 2023
13 March 2024
Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema
TA953
13 March 2024
13 March 2024
Previous page
1
Current page
2
3
4
…
49
Page
2
of
49
Next page
Results per page
10
25
50
All
Back to top